

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/077082 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/004281

(22) International Filing Date: 11 February 2005 (11.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/543,756 11 February 2004 (11.02.2004) US

(71) Applicant (for all designated States except US): UNI-
VERSITY OF VIRGINIA PATENT FOUNDATION
[US/US]; 1224 West Main Street, Ste 1-110, Char-
lottesville, VA 22903 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRAY, LLOYD, S.

[US/US]; 2955 Cove Trce, Charlottesville, VA 22911 (US).
MACDONALD, Timothy, L. [US/US]; P.O. Box 262, Ivy,
VA 22945 (US).







(74) Agent: GROLZ, Edward, W.; Scully, Scott, Murphy &
Presser, 400 Garden City Plaza, Ste 300, Garden City, NY
11530 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: INHIBITING CAV3 ISOFORMS AND THE $\delta 25B$ SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT
OF CANCER



(57) Abstract: The invention provides a pharmaceutical composition comprising an antibody that specifically binds to a Cav3 isoform or its $\delta 25$ splice variants thereof. The present invention also relates to compositions and methods for inhibiting cancer cell proliferation, preventing, treating and/or controlling cancer and/or related disorders in a patient by administering to the patient a therapeutically effective amount of the T type calcium channel selective inhibitor. A preferred T type calcium channel selective inhibitor is mibefradil.

WO 2005/077082 A2

BEST AVAILABLE COPY



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.